A Post-marketing Clinical Study to Confirm the Efficacy of &lt;sup&gt;18&lt;/sup&gt;F-fluorodeoxyglucose for the Diagnosis of Myocardial Viability

Matsunari, Ichiro; Tamaki, Nagara; Ikeda, Masatoshi; Naito, Hiroyuki; Okazaki, Osamu; Sato, Miki; Iida, Kei; Iwado, Yasuyoshi; Sakai, Shuji; Nagamachi, Shigeki; Kumita, Shin‐ichiro; Sugiura, Nami; Teramachi, Masako

doi:10.17996/anc.16001

Cited by 4 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When stress myocardial perfusion SPECT fails in complete assessment of myocardial viability, fluorine 18-labeled fluorodeoxyglucose ( 18 F FDG) PET is advised. 59 A "blood flow and glucose metabolism dissociation" suggests myocardial viability (hibernating myocardium). In an observational study of 648 patients with impaired cardiac function (left ventricular ejection fraction [LVEF] 31±12%), survival rate was increased by early revascularization only in patients for whom blood flow and glucose metabolism dissociation had been noted by rest-stress 82 Rb/ 18 F FDG PET, with a particularly greater benefit of revascularization observed among patients with >10% viable myocardium.…”

Section: Myocardial Viabilitymentioning

confidence: 99%

JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease

Nakamura

Yaku

Ako

et al. 2022

Circ J

View full text Add to dashboard Cite

Section: Myocardial Viabilitymentioning

confidence: 99%

JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease

Nakamura

Yaku

Ako

et al. 2022

Circ J

View full text Add to dashboard Cite

<sup>18</sup>F-FDG PET Viability Assessment for the Improvements of Prognosis of the Patients with Left Ventricular Dysfunction

Matsuo

Yoshinaga²

2016

Annals of Nuclear Cardiology

View full text Add to dashboard Cite

show abstract

Assessment of Myocardial Blood Flow and Cardiac FDG Uptake Using Positron Emission Tomography

Manabe

Naya

Yoshinaga

et al. 2017

Annals of Nuclear Cardiology

Self Cite

View full text Add to dashboard Cite

Cardiac positron emission tomography (PET) has evolved over the several decades since its introduction. In current clinical practice and research, cardiac PET imaging is accepted as a valuable noninvasive modality for assessing various cardiac diseases such as coronary artery disease (CAD), cardiac tumors, and inflammatory diseases including cardiac sarcoidosis (CS). PET enables the imaging and evaluation of the cardiovascular system by myocardial perfusion with 82 Rb, 13 N-NH3 and 15 O-H2O, and those of metabolism and inflammation using 18 F- fluorodeoxyglucose ( 18 F-FDG). PET has demonstrated superior diagnostic accuracy for the detection of CAD andalso has well-established prognostic value. The combination of qualitative and absolute quantifications of myocardial blood flow enhances the diagnostic accuracy for multiple-vessel disease and provides incremental functional and prognostic information. In this review, we focus on the current and future roles of cardiac PET imaging, on the basis of our own experience.

show abstract

A Post-marketing Clinical Study to Confirm the Efficacy of <sup>18</sup>F-fluorodeoxyglucose for the Diagnosis of Myocardial Viability

Cited by 4 publications

References 21 publications

JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease

JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease

<sup>18</sup>F-FDG PET Viability Assessment for the Improvements of Prognosis of the Patients with Left Ventricular Dysfunction

Assessment of Myocardial Blood Flow and Cardiac FDG Uptake Using Positron Emission Tomography

Contact Info

Product

Resources

About